A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.
Similar Posts
Compounding when Drugs are on FDA’s Drug Shortages List
FDA understands that when a drug is in shortage, patients and health care professionals may look to compounded drugs as an option to get the medication they need.CDL Services, Inc. DBA Technichem – 713877 – 11/24/2025
CGMP/Finished Pharmaceuticals/AdulteratedSprout Organics Expands Voluntary Recall of Sweet Potato Apple and Spinach to Include Additional Lot Codes
Sprout Organics is expanding its September 16, 2025 recall of Sprout Organics® Sweet Potato Apple and Spinach, due to potentially elevated lead levels, to include additional lots.Ideal Specialty Apothecary Inc., dba Ideal Pharmacy, Union, NJ. 483 Issued 08/31/2017
Ideal Specialty Apothecary Inc., dba Ideal Pharmacy, Union, NJ. 483 Issued 08/31/2017Task Description Request Please post to the 2017 Pharmacy Inspections and Related Records Web page
Record Date 08/31/2017
FEI Number 3013505558
Firm Name Ideal Specialty Apothecary Inc., dba Ideal Pharmacy
RecordAdvancing Clinical Trial Participation for the LGBTQIA+ Community
Representatives of the FDA were fortunate to attend a community discussion on advancing clinical trial diversity for sexual and gender minority communities to help improve the generalizability of trial results across the entire population of patients who may use medical products.Verified Clinical Benefit | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.